… , apixaban), vitamin K antagonists (VKA), such as warfarin and acenocoumarol are still the
most widely used oral anticoagulants for the treatment of nonvalvular atrial fibrillation … practice. …

… for AF from >4600 physicians' prescriptions in France, Germany and the UK during 2015 that
… apixaban, in clinical practice 44% of patients received the low dose; and whereas 20.7% of …

… II, and rivaroxaban, apixaban and edoxaban inhibit activated … of NOACs versus warfarin in
patients with atrial fibrillation (AF), … [4] [5] With increasing use of NOACs in clinical practice,[6] …

… %) included patients with atrial fibrillation treated with DOAC for … age for patients treated
with apixaban and rivaroxaban … , Italian and German studies compared with the patients in the …

… (NVAF) compared rivaroxaban, dabigatran, and apixaban with … used vitamin K antagonist
(VKA) in Germany, are scarce. … 175,994 NVAF patients from German clinical practice initiating …

… and safely in clinical practice. Many unresolved questions on how to optimally … vitamin K
antagonists (VKAs) for thromboembolic prevention in patients with non-valvular atrial fibrillation (…

… with acute ischaemic stroke in a German university hospital. … are at least equally effective
to the vitamin K antagonist (VKA) … rivaroxaban as well as apixaban was more often prescribed …

… as an alternative to vitamin K antagonists (VKAs) and are … to describe the routine clinical
practice use of apixaban and other … atrial fibrillation in unselected patients in Germany. Results …

… type of OAC in routine clinical practice [11]. Moreover, VKA … quality methods for comparative
effectiveness research, dabigatran … compared to warfarin, while apixaban was not (Figure 4). …

… evaluations in post-ACS patients with AF. In … of apixaban was studied both after ACS 27
and in AF. The data show significant excess in bleeding and no efficacy post-ACS with apixaban …